Impact of hyperuricemia on the clinical outcomes in patients with polycystic ovary syndrome undergoing in vitro fertilization and embryo transfer
10.3760/cma.j.cn101441-20240430-00156
- VernacularTitle:高尿酸血症对多囊卵巢综合征患者体外受精-胚胎移植助孕临床结局的影响
- Author:
Ting ZHANG
1
;
Haoying HAO
;
Siyue XU
;
Nan JIA
;
Lifeng TIAN
;
Shaodi ZHANG
Author Information
1. 长沙市第三医院内分泌代谢科，长沙 410015
- Publication Type:Journal Article
- Keywords:
Uric acid;
Fertilization in vitro;
Embryo transfer;
Polycystic ovary syndrome;
Live birth rate;
Cumulative live birth rate
- From:
Chinese Journal of Reproduction and Contraception
2024;44(12):1235-1241
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the impact of hyperuricemia on the live birth rate per transfer cycle and the cumulative live birth rate per oocyte retrieval cycle in patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization and embryo transfer (IVF-ET). Methods:A retrospective cohort study was conducted on data from 3 959 PCOS patients who received IVF-ET treatment at the Reproductive Centers of Henan Provincial People's Hospital and Jiangxi Provincial Maternal and Child Health Hospital between January 2016 and December 2021. The patients were divided into hyperuricemia group (>357 μmol/L, n=1 126) and normal uric acid group (≤357 μmol/L, n=2 833) based on their uric acid levels. Baseline data, clinical and laboratory indicators were compared between the two groups. Univariate and multivariate regression analyses were performed on factors influencing clinical outcomes. Multivariate logistic regression analysis was used to compare the live birth rate per transfer cycle and the cumulative live birth rate per oocyte retrieval cycle between the two groups, clarifying the impact of hyperuricemia on clinical outcomes in PCOS patients. Results:There were no significant differences between the two groups in terms of age, duration of infertility, baseline testosterone level, type of infertility, and the rate of unusable embryos (all P>0.05). Body mass index [BMI, (25.15±3.75) kg/m 2], fasting blood glucose [(4.99±0.80) mmol/L] and fasting insulin levels [17.19 (11.78, 25.30) mU/L] in hyperuricemia group were higher than those in normal uric acid group [(23.60±3.64) kg/m 2, P<0.001; (4.88±0.81) mmol/L, P<0.001;12.40 (8.59, 17.86) mU/L, P<0.001], while their baseline luteinizing hormone [7.62 (4.68, 11.18) U/L] and anti-Müllerian hormone [7.62 (5.34, 10.73) μg/L] levels were lower than those in normal uric acid group [7.88 (4.98, 11.91) U/L, P=0.024; 7.95 (5.49, 11.73) μg/L, P<0.001], with statistically significant differences. Multivariate logistic regression analysis indicated that female BMI, endometrial thickness on human chorionic gonadotropin (hCG) injection day, and the number of transferable embryos were factors influencing the live birth rate per transfer cycle ( OR=1.02, 95% CI: 1.00-1.04, P=0.044; OR=0.95, 95% CI: 0.92-0.97, P<0.001; OR=0.97, 95% CI: 0.95-0.99, P=0.006). Fasting blood glucose, endometrial thickness on hCG injection day, and the number of transferable embryos were factors influencing the cumulative live birth rate per oocyte retrieval cycle ( OR=1.14, 95% CI: 1.01-1.29, P=0.036; OR=0.92, 95% CI: 0.87-0.97, P=0.002; OR=0.70, 95% CI: 0.66-0.75, P<0.001). Compared with the normal uric acid group, the hyperuricemia group in PCOS patients had not a statistically signifcant decrease in the live birth rate per transfer cycle and the cumulative live birth rate per oocyte retrieval cycle ( OR=0.93, 95% CI: 0.72-1.19, P=0.548; OR=1.18, 95% CI: 0.87-1.60, P=0.300). Conclusion:Hyperuricemia does not affect the live birth rate per transfer cycle or the cumulative live birth rate per oocyte retrieval cycle in PCOS patients undergoing IVF-ET.
